{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+level+3&page=29",
    "query": {
      "intervention": "Dose level 3",
      "page": 29
    },
    "page_size": 10
  },
  "pagination": {
    "page": 29,
    "page_size": 10,
    "total_count": 17830,
    "total_pages": 1783,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+level+3&page=30&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+level+3&page=28&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T05:02:42.993Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00577096",
      "title": "Effects of Exercise in Combination With Epoetin Alfa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Epoetin Alfa",
          "type": "DRUG"
        },
        {
          "name": "Exercise",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Autologous Peripheral Blood Stem Cell Transplantation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Red Blood Cell Transfusion",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Thalidomide",
          "type": "DRUG"
        },
        {
          "name": "Heparin, Low-Molecular-Weight",
          "type": "DRUG"
        },
        {
          "name": "Platelet Transfusion",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Total Therapy II",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL",
        "BIOLOGICAL"
      ],
      "sponsor": "University of Arkansas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 120,
      "start_date": "2001-10",
      "completion_date": "2004-06",
      "has_results": true,
      "last_update_posted_date": "2015-04-06",
      "last_synced_at": "2026-11-15T05:02:42.993Z",
      "location_count": 1,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00577096"
    },
    {
      "nct_id": "NCT03140488",
      "title": "Oxytocin Dosage to Decrease Induction Duration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Obesity",
        "Labor, Induced",
        "Oxytocin"
      ],
      "interventions": [
        {
          "name": "Oxytocin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Arizona",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 140,
      "start_date": "2017-06-05",
      "completion_date": "2019-09-05",
      "has_results": true,
      "last_update_posted_date": "2022-12-20",
      "last_synced_at": "2026-11-15T05:02:42.993Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03140488"
    },
    {
      "nct_id": "NCT00587873",
      "title": "Sequential Administration of Oral 6-Thioguanine (6-TG) After Methotrexate (MTX) in Patients With Relapsed Hodgkin's Disease (Phase II)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hodgkin's Disease"
      ],
      "interventions": [
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin calcium",
          "type": "DRUG"
        },
        {
          "name": "6-Thioguanine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 18,
      "start_date": "1994-03",
      "completion_date": "2009-06",
      "has_results": false,
      "last_update_posted_date": "2009-06-12",
      "last_synced_at": "2026-11-15T05:02:42.993Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00587873"
    },
    {
      "nct_id": "NCT01178073",
      "title": "A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypertension, Pulmonary"
      ],
      "interventions": [
        {
          "name": "ambrisentan",
          "type": "DRUG"
        },
        {
          "name": "tadalafil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 610,
      "start_date": "2010-10-01",
      "completion_date": "2014-07-31",
      "has_results": true,
      "last_update_posted_date": "2017-09-13",
      "last_synced_at": "2026-11-15T05:02:42.993Z",
      "location_count": 61,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 50 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01178073"
    },
    {
      "nct_id": "NCT04186520",
      "title": "CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non Hodgkin Lymphoma (NHL)",
        "Mantle Cell Lymphoma (MCL)",
        "Chronic Lymphocytic Leukemia (CLL)",
        "Follicular Lymphoma",
        "Marginal Zone Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "Primary Mediastinal Large B-cell Lymphoma (PMBCL)",
        "Central Nervous System Lymphoma"
      ],
      "interventions": [
        {
          "name": "8/12-Day Production of Car-T Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "8/12-Day Production of Cryopreserved Car-T Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "12-Day Production of Car-T Cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 100,
      "start_date": "2020-05-18",
      "completion_date": "2029-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-02-23",
      "last_synced_at": "2026-11-15T05:02:42.993Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04186520"
    },
    {
      "nct_id": "NCT01056159",
      "title": "A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Albuterol dry powder inhaler",
          "type": "DRUG"
        },
        {
          "name": "Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 47,
      "start_date": "2010-01",
      "completion_date": "2010-06",
      "has_results": false,
      "last_update_posted_date": "2022-02-02",
      "last_synced_at": "2026-11-15T05:02:42.993Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Denver, Colorado • Lakewood, Colorado + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Normal",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01056159"
    },
    {
      "nct_id": "NCT07563296",
      "title": "KALM-B: Ketamine-assisted Psychotherapy (KAP) to Lessen Morbidity After Burn Injury",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "PTSD and Trauma-related Symptoms"
      ],
      "interventions": [
        {
          "name": "Preparatory Session",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Ketamine-assisted Psychotherapy Session #1",
          "type": "DRUG"
        },
        {
          "name": "Ketamine-assisted Psychotherapy Session #2",
          "type": "DRUG"
        },
        {
          "name": "Integration Session",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG"
      ],
      "sponsor": "Irma Fleming",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 12,
      "start_date": "2026-08-24",
      "completion_date": "2028-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-11-15T05:02:42.993Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07563296"
    },
    {
      "nct_id": "NCT06904313",
      "title": "Ultralow Dose PET Imaging for PSMA Expression",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Healthy Volunteer",
        "Prostate CA"
      ],
      "interventions": [
        {
          "name": "Piflufolastat F18",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Akiva Mintz",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 200,
      "start_date": "2025-05-12",
      "completion_date": "2030-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-06-04",
      "last_synced_at": "2026-11-15T05:02:42.993Z",
      "location_count": 1,
      "location_summary": "Englewood, New Jersey",
      "locations": [
        {
          "city": "Englewood",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06904313"
    },
    {
      "nct_id": "NCT03713320",
      "title": "SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cutaneous T-Cell Lymphoma/Mycosis Fungoides"
      ],
      "interventions": [
        {
          "name": "Cobomarsen",
          "type": "DRUG"
        },
        {
          "name": "Vorinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "miRagen Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2019-04-02",
      "completion_date": "2020-12-01",
      "has_results": true,
      "last_update_posted_date": "2022-04-08",
      "last_synced_at": "2026-11-15T05:02:42.993Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03713320"
    },
    {
      "nct_id": "NCT05312879",
      "title": "Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Proteinuric Kidney Disease"
      ],
      "interventions": [
        {
          "name": "VX-147",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "10 Years to 65 Years"
      },
      "enrollment_count": 522,
      "start_date": "2022-03-30",
      "completion_date": "2030-05-07",
      "has_results": false,
      "last_update_posted_date": "2026-10-26",
      "last_synced_at": "2026-11-15T05:02:42.993Z",
      "location_count": 223,
      "location_summary": "Alabaster, Alabama • Birmingham, Alabama • Fairhope, Alabama + 144 more",
      "locations": [
        {
          "city": "Alabaster",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05312879"
    }
  ]
}